About T3 Pharma
T3 Pharma is a Healthcare company based in Basel (Switzerland) founded in 2015, and was acquired by Boehringer Ingelheim in November 2023. Novel cancer medicines are developed using a bacteria-based platform. It operates on a HealthTech model. T3 Pharma has raised $38.83 million across 3 funding rounds from investors including Boehringer Ingelheim, Wille Finance and Boehringer Ingelheim Venture Fund. T3 Pharma offers products and services including Immuno-Oncology Therapy. Its focus areas include Biotechnology and Immuno-Oncology. Its legal entity is T3 Pharmaceuticals AG.
Company details
T3 Pharma is engaged in the development of innovative immuno-oncology therapies. The company operates within the biotechnology sector, targeting cancer treatment solutions. Research and technology are utilized to create advanced therapeutic options for patients. The focus is maintained on addressing unmet medical needs in oncology.
- Headquarters Basel, Switzerland
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website t3pharma.com
- Social LinkedIn X
- Acquired by Boehringer Ingelheim (Nov 2023)
- Legal Name T3 Pharmaceuticals Ag
- Total Equity Funding$38.83M (USD)
in 3 rounds
- Latest Funding Round$26.69M (USD), Series C
Jul 2020
- InvestorsBoehringer Ingelheim
& 3 more
- Acquired byBoehringer Ingelheim
(Nov 2023)
Products & Services of T3 Pharma
T3 Pharma offers a comprehensive portfolio of products and services, including Immuno-Oncology Therapy.
Innovative therapies are developed for cancer treatment solutions.
Funding Insights of T3 Pharma
T3 Pharma has successfully raised a total of $38.83M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $26.69 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $38.83M
- Total Rounds 3
- Last Round Series C — $26.69M
- First Round $61,200
(Jul 2016)
- Investors Count 3
All 3 funding rounds of T3 Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $26.69M | Series C | – | Wille Finance, Boehringer Ingelheim Venture Fund | |
| Sep 2019 | $12.14M | Series B | – | Boehringer Ingelheim Venture Fund | |
| Jul 2016 | $61,200 | Grant | – | – | – |
4 investors in total: 4 institutional.
Investors in T3 Pharma
T3 Pharma has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Boehringer Ingelheim, Wille Finance and Boehringer Ingelheim Venture Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in real estate, digital media, and tech. | willefinance.com | Zurich, Switzerland | ||
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund. | boehringer-ingelheim-venture.com | |||
| referencecap.com | ||||
Generic drugs and clinical research services are provided globally. | 1885 | boehringer-ingelheim.com |
Investor details for T3 Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of T3 Pharma
13 people are tracked at T3 Pharma (6 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
Debora Schmitz-Rohmer | Head of Development | Leadership |
Marlise Amstutz | Executive director microbiology and co-founder | Leadership |
Simon Ittig | CEO and Co-founder | Leadership |
Falk Saupe | Head of In Vivo Pharmacology | Leadership |
Gabriella Galli | Head Of Clinical Operations | Leadership |
Christoph Kasper | CSO and Co-founder | Leadership |
Christian Arquint | CMC project manager / Senior scientist | Team |
Christoph Schmutz | Senior Scientist /CMC Project Manager at T3 Pharmaceuticals AG | Team |
Mélodie Duval | Senior Scientist | Team |
Jonas Fürst | Phd Student | Team |
Simon Marlaire | Senior Researcher | Team |
Tiphaine Haas | Junior Researcher | Team |
Alain Mazé | Senior Scientist | Team |
Complete people profiles for T3 Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of T3 Pharma
4 dated milestones of T3 Pharma across 8 years, from founding to its latest funding, stage changes and deals.
- Founded T3 Pharma is founded.
- Funding First funding round of $61K.
- Funding Latest funding round, Series C, of $26.7M.
- Exit Acquired by Boehringer Ingelheim.
Web traffic of T3 Pharma
The website of T3 Pharma (t3pharma.com) receives about 2.1K visits a month.
- Monthly visits2.1K
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about T3 Pharma
Complete news archive for T3 Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about T3 Pharma
T3 Pharma was founded in 2015 and raised its 1st funding round 1 year after it was founded.
T3 Pharma is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
T3 Pharma is a funded company, having raised a total of $38.83M across 3 funding rounds to date. The company's 1st funding round was a Grant of $61.2K, raised on Jul 2016.
T3 Pharma is engaged in the development of innovative immuno-oncology therapies. The company operates within the biotechnology sector, targeting cancer treatment solutions. Research and technology are utilized to create advanced therapeutic options for patients. The focus is maintained on addressing unmet medical needs in oncology.
T3 Pharma offers Immuno-Oncology Therapy.
T3 Pharma has 4 investors. Key investors include Boehringer Ingelheim, Wille Finance, Boehringer Ingelheim Venture Fund, and Reference Capital.
T3 Pharma operates through T3 Pharmaceuticals Ag.
Yes. T3 Pharma was acquired by Boehringer Ingelheim in November 2023.